Antiretroviral Therapy, Highly ActiveAnti-HIV AgentsHIV InfectionsAnti-Retroviral AgentsCD4 Lymphocyte CountNevirapineBenzoxazinesHIV Protease InhibitorsHIV-1Viral LoadReverse Transcriptase InhibitorsStavudineRitonavirDrug Resistance, ViralInfectious Disease Transmission, VerticalZidovudineNelfinavirDrug Therapy, CombinationLopinavirOrganophosphonatesOxazinesHIVLamivudineRNA, ViralDideoxynucleosidesTreatment FailureAdenineDrug Resistance, Multiple, ViralPatient CompliancePyrimidinonesDidanosineAcquired Immunodeficiency SyndromeSaquinavirTreatment OutcomePregnancy Complications, InfectiousDrug Administration ScheduleCohort StudiesHIV Fusion InhibitorsPyrrolidinonesProspective StudiesPregnancyRetrospective StudiesMedication AdherenceSouth AfricaAIDS-Related Opportunistic InfectionsFollow-Up StudiesTime FactorsRisk FactorsGenotypeInfant, NewbornHIV-Associated Lipodystrophy SyndromeHIV SeropositivityUgandaIndinavirViremiaCD4-Positive T-LymphocytesImmune Reconstitution Inflammatory SyndromeBotswanaLost to Follow-UpHIV Reverse TranscriptaseAIDS Dementia ComplexMalawiDrug MonitoringCoinfectionDirectly Observed TherapyCote d'IvoireAfrica South of the SaharaHIV ProteaseAntitubercular AgentsAntineoplastic Combined Chemotherapy ProtocolsZambiaLymphoma, AIDS-RelatedLipodystrophyDisease ProgressionCross-Sectional StudiesAfrica, SouthernTuberculosisDeveloping CountriesVirus ReplicationAntiviral AgentsSurvival AnalysisZimbabwePlasmaPrevalenceCytomegalovirus RetinitisDrug InteractionsHIV Wasting SyndromeLesothoDrug CombinationsLongitudinal StudiesIncidencepol Gene Products, Human Immunodeficiency VirusWithholding TreatmentTreatment RefusalCyclophosphamideHIV Integrase InhibitorsClinical Trials as TopicCD4-CD8 RatioCD8-Positive T-LymphocytesMultivariate Analysis